Approvals to Bevqolva, the bevacizumab biosimilar of the company’s subsidiary Aurobindo Pharma, and recent observations by the United States food and drug administration, make this companies stocks important.

Aurobindo Pharma Inc will be non-event for share price on 23rd December of the year when it step down subsidiary CuraTeQ Biologics got marketing authorization for biosimilar bevacizumab product Bevqolva from Medicines and Healthcare Products Regulatory Agency of United Kingdom. The will be in two forms of infusion dosage; a 4ml of 100mg and 16ml of 400mg.

Bevacizumab is used for the treatment of several types of tumors: those of metastasizing colorectal malignancy, non-small cell bronchiogenic carcinoma, and ovarian carcinoma. At the same time, the inclusion of Bevqolva is a victory for Aurobindo Pharma to progress into a greater array of biosimilar oncology.

However, the company has also last week came under US Food and Drug Administration (USFDA) that got two observations after inspecting the Unit-V API manufacturing facility in Telangana.